CoChat

The Economic Burden of Allergic Rhinitis: A Critical Evaluation of the Literature

Reed, Shelby D, Lee, Todd A, McCrory, Douglas C · 2004 · PharmacoEconomics

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

Although a large number of economic analyses of allergic rhinitis have been published, there are relatively few empirically based studies, particularly outside the US. The majority of these analyses can be classified as burden-of-illness studies. Most estimates of the annual cost of allergic rhinitis range from dollars US 2-5 billion (2003 values). The wide range of estimates can be attributed to differences in identifying patients with allergic rhinitis, differences in cost assignment, limitations associated with available data and difficulties in assigning indirect costs (associated with reduced productivity) of allergic rhinitis. Approximately one-third of burden-of-illness studies include direct and indirect costs of allergic rhinitis, about one-third focus on direct costs only, and the remaining one-third focus exclusively on indirect costs due to reduced productivity. Indirect costs attributable to allergic rhinitis were higher in studies only estimating indirect costs (dollars US 5.5-9.7 billion) than in those estimating both direct and indirect costs (dollars US 1.7-4.3 billion). Although there are many economic evaluations of allergic rhinitis treatments in the published medical literature, very few represent formal cost-effectiveness evaluations that compare the incremental costs and benefits of alternative treatment strategies. Those that are incremental cost-effectiveness analyses have several limitations, including small samples, short study periods and the lack of a standardized measure of effectiveness. To date, the medical literature is lacking a comprehensive economic evaluation of general treatment strategies for allergic rhinitis. In undertaking such an analysis, serious consideration must be given to the study population of interest, the choice of appropriate comparators, the perspective from which the analysis is conducted, the target audience, the changing healthcare marketplace and the selection of a measure of effectiveness that incorporates both positive and negative aspects of treatments for allergic rhinitis. Future work would benefit from the development of a consensus on a summary measure of effectiveness that could be used in cost-effectiveness analyses of therapies for allergic rhinitis as well as additional empirical work to measure the association between severity of disease and its impact on worker productivity.

Overview

Integrity signals

Registry

Crossref · 10.2165/00019053-200422060-00002

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 67 references

Research works printed but not linked: 14

  1. McMenamin, 1994, Ann Allergy, 73, 35
  2. Malone, 1997, J Allergy Clin Immunol, 99, 22
  3. Mackowiak, 1997, Am J Manag Care, 3, S8
  4. Ross, 1996, Am J Manag Care, 2, 285
  5. Crystal-Peters, 2000, Am J Manag Care, 6, 373
  6. Stempel, 1998, Am J Manag Care, 4, 89
  7. Hindmarch, 2001, Curr Med Res Opin, 17, 273, 10.1185/0300799019117014 · doi:10.1185/0300799019117014
  8. Yanez, 2002, Ann Allergy Asthma Immunol, 89, 479, 10.1016/S1081-1206(10)62085-6 · DOI · Paper page
  9. Trotter, 2000, Manag Care Interface, 13, 60
  10. Liao, 2001, Am J Manag Care, 7, S459
  11. Carvalho, 2000, Allergol Immunopathol (Madr), 28, 207
  12. Asher, 2001, N Z Med J, 114, 114
  13. Tanner, 1999, Am J Manag Care, 5, S235
  14. Crown, 2000, Drug Benefit Trends, 12, 5BH

Cited by

See all 222

Metadata

Authors
Reed, S. D., Lee, T. A., & McCrory, D. C.
Affiliations
  • Duke Medical Center (US)
  • Northwestern University (US)
  • Duke University (US)
Corresponding author
Reed, Shelby D
Venue
PharmacoEconomics
Published
2004
Volume
22
Issue
6
Pages
345-361
ISSN
1170-7690 (ISSN-L)
OpenAlex
W2080356144
Cited by
222
References
67
Citations by year
2026: 4 · 2025: 7 · 2024: 7 · 2023: 13 · 2022: 4 · 2021: 7 · 2020: 9 · 2019: 5 · 2018: 6 · 2017: 9 · 2016: 9 · 2015: 9 · 2014: 10 · 2013: 12 · 2012: 11
FWCI
0.82
Type
journal article
Language
en
Open access
closed
Locations
  • PharmacoEconomics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • Agency for Healthcare Research and Quality
Topics
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Keywords
allergic rhinitis, economic burden, direct costs, indirect costs, productivity loss, cost-effectiveness analysis, treatment options, disease severity, health care costs
MeSH terms
Histamine H1 Antagonists, Humans, Quality of Life, Rhinitis, Allergic, Perennial, United States, Cost of Illness, Economics, Pharmaceutical, Anti-Allergic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Economic Burden of Allergic Rhinitis: A Critical Evaluation of the Literature. https://app.cochat.ai/papers/10.2165/00019053-200422060-00002
The paper
Reed, S. D., Lee, T. A., & McCrory, D. C. (2004). The Economic Burden of Allergic Rhinitis: A Critical Evaluation of the Literature. PharmacoEconomics. https://doi.org/10.2165/00019053-200422060-00002

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.